Skip to main content

Table 1 Seroconversion testing granted emergency authorization by the WHO (reference in text [4,5,6])

From: Should we vaccinate the better seroconverters or the most vulnerable? Game changing insights for COVID-19 vaccine prioritization policies

o Trade name Type Dosage interval Least interval for antibody testing after vaccinationa
mRNA-1273 Moderna mRNA-based 2 doses, 28 days apart 14 days after 2nd dose
BNT162b2 Pfizer/BionTech mRNA-based 2 doses, 21 days apart 7 days after 2nd dose
Ad26.COV2.S Janssen (Johnson&Johnson) Non-replicating viral vector 1 dose or 2 doses 56 days apart 14 days after 2nd dose
AZD1222 Oxford/AstraZeneca Non-replicating viral vector 2 doses, 28 days apart 14 days after 2nd dose
BBIBP-CorV (Vero Cells) Sinopharm (Beijing) Inactivated 2 doses with 2–4 weeks interval between 14 days after 2nd dose
CoronaVac Sinovac Inactivated 2 doses with 2–4 weeks interval between 14 days after 2nd dose
  1. Ad adenovirus, AZ Astrazeneca, BBIBP-CorV Beijing Institute of Biological Products, Sinopharm corona virus vaccine, BNT Biontech, CoV coronaviridae, COVID-19 coronavirus disease 2019, mRNA messenger ribonucleic acid, SARS severe acute respiratory syndrome, WHO World Health Organization
  2. aStandard antibody test: total immunoglobulin levels to the receptor-binding domain of the SARS-CoV-2 spike protein were measured with an anti–SARS-CoV-2 S enzyme immunoassay